enfermedad de Parkinson
Última actualización 3 Apr 2025
Cumple con las directrices editoriales
- DescargarDescargar
- Compartir
- Language
- Discusión
- Versión en audio
- Agregar a fuentes preferidas en Google
Parkinson's disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.
Descripción
Parkinson's disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.
Often the first symptom of Parkinson's disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson's disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.
Parkinson's disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson's disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgement and memory.
Generally, Parkinson's disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson's disease.
Patrones de herencia
The source lists the following possible inheritance patterns: Autosomal dominant+1 affected parent; Autosomal recessive; Pattern unknown. More than one pattern can apply in different cases.
Related genes
Otros nombres
Parkinson disease
PD
Primary parkinsonism
Related patient information and medicines

Patient information leaflet
enfermedad de Parkinson
The main symptoms of Parkinson's disease are usually stiffness, shaking (tremor), and slowness of movement. What is Parkinson's disease. Parkinson's disease is a progressive neurological degeneration of certain cells (called dopaminergic cells) within a specific part of the brain (substantia nigra). Parkinson's disease symptoms The brain cells and.

Medicine leaflet
Apomorfina para la enfermedad de Parkinson
Apomorphine is used for 'off' episodes in Parkinson's disease. About apomorphine Type of medicine Dopamine-receptor agonist Used for enfermedad de Parkinson Also called APO-go®, Dacepton® Available as Pen injector, cartridges or pre-filled syringe enfermedad de Parkinson is a disorder of the brain. Parkinson's disease, some of the cells in the substantia.

Medicine leaflet
Tolcapona para la enfermedad de Parkinson
Tolcapone will be recommended for you by a specialist doctor who will continue to check on your progress. About tolcapone Type of medicine A dopaminergic medicine called a catechol-O-methyltransferase inhibitor Used for enfermedad de Parkinson Also called Tasmar® Available as Tablets enfermedad de Parkinson affects the way your brain co-ordinates the.

Medicine leaflet
Selegilina para la enfermedad de Parkinson
About selegiline Type of medicine A monoamine-oxidase-B inhibitor Used for enfermedad de Parkinson Also called Eldepryl® Available as Tablets The symptoms of enfermedad de Parkinson - tremor, stiffness and slow movement - are due to there being less of a chemical called dopamine in your brain. Selegiline works by increasing the effect of dopamine in the.

Medicine leaflet
Co-beneldopa para la enfermedad de Parkinson
Co-beneldopa is a medicine which has been prescribed for many years for people with Parkinson's disease. About co-beneldopa Type of medicine A dopaminergic medicine Used for enfermedad de Parkinson in people over 25 years of age Also called Madopar® Available as Capsules, dispersible tablets and prolonged-release capsules You will have been prescribed.

Patient information leaflet
Enfermedad de Alzheimer
Lifestyle factors that also increase the risk of cardiovascular disease and cerebrovascular disease - for example, smoking, lack of physical exercise, and an unh... Parkinson's disease. People with Down's syndrome. Alzheimer's disease symptoms Alzheimer's disease is a progressive condition, which means the symptoms gradually become more severe.
Lecturas adicionales y referencias
- enfermedad de Parkinson; MedlinePlus, National Library of Medicine.
- Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 2006 Mar;7(3):207-19. doi: 10.1038/nrn1868.
- Cookson MR, Bandmann O. Parkinson's disease: insights from pathways. Hum Mol Genet. 2010 Apr 15;19(R1):R21-7. doi: 10.1093/hmg/ddq167. Epub 2010 Apr 26.
- Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev. 2011 Oct;91(4):1161-218. doi: 10.1152/physrev.00022.2010.
- Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006 Apr;7(4):306-18. doi: 10.1038/nrg1831.
- Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol. 2005 Aug;18(4):363-9. doi: 10.1097/01.wco.0000170951.08924.3d.
- Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann Neurol. 2006 Oct;60(4):389-98. doi: 10.1002/ana.21022.
- Huang Y, Cheung L, Rowe D, Halliday G. Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev. 2004 Aug;46(1):44-70. doi: 10.1016/j.brainresrev.2004.04.007.
- Jain S, Wood NW, Healy DG. Molecular genetic pathways in Parkinson's disease: a review. Clin Sci (Lond). 2005 Oct;109(4):355-64. doi: 10.1042/CS20050106.
- Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond. Mov Disord. 2009 Oct 30;24(14):2042-58. doi: 10.1002/mds.22675.
- Lewthwaite AJ, Nicholl DJ. Genetics of parkinsonism. Curr Neurol Neurosci Rep. 2005 Sep;5(5):397-404. doi: 10.1007/s11910-005-0064-6.
- Morris HR. Genetics of Parkinson's disease. Ann Med. 2005;37(2):86-96. doi: 10.1080/07853890510007269.
- Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat. 2010 Jul;31(7):763-80. doi: 10.1002/humu.21277.
- Pankratz N, Foroud T. Genetics of Parkinson disease. NeuroRx. 2004 Apr;1(2):235-42. doi: 10.1602/neurorx.1.2.235.
- Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004 May 29;363(9423):1783-93. doi: 10.1016/S0140-6736(04)16305-8.
- Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Durr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61. doi: 10.1056/NEJMoa0901281.
- Singleton AB. Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. Trends Neurosci. 2005 Aug;28(8):416-21. doi: 10.1016/j.tins.2005.05.009.
- Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat. 2007 Jul;28(7):641-53. doi: 10.1002/humu.20507.
- Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 Jun 1;157(11):1015-22. doi: 10.1093/aje/kwg068.
- Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med. 2004 Jul;10 Suppl:S58-62. doi: 10.1038/nm1068.
- von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77. doi: 10.1016/j.pneurobio.2004.05.002.
Únete a la conversación
Comparte tus pensamientos o experiencias con otros en nuestro comunidades de pacientes.

Pregunta, comparte, conecta.
Navega por discusiones, haz preguntas y comparte experiencias en cientos de temas de salud.
Suscríbete al boletín de Patient
Tu dosis semanal de consejos de salud claros y confiables, escritos para ayudarte a sentirte informado, seguro y en control.
Al suscribirte aceptas nuestros Política de Privacidad. Puedes darte de baja en cualquier momento. Nunca vendemos tus datos.